Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.56 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TACR3 | P29371 | 3/20 | 0.51 |
| ▸ | TACR2 | P21452 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3376152 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNATSHRKDM4EHPGD | |
| SCHEMBL3370482 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNATSHRKDM4EHPGD | |
| SCHEMBL15093820 | 0.88 | EPHX2 (0.65) | ALDH1A1LMNATSHRKDM4EHPGD | |
| SCHEMBL186238 | 0.86 | LMNA (0.61) | ALDH1A1LMNATSHRKDM4EHPGD | |
| SCHEMBL186230 | 0.86 | LMNA (0.61) | ALDH1A1LMNATSHRKDM4EHPGD | |
| SCHEMBL186416 | 0.86 | LMNA (0.61) | ALDH1A1LMNATSHRKDM4EHPGD | |
| SCHEMBL3352726 | 0.85 | LMNA (0.53) | ALDH1A1LMNATSHRKDM4EHPGD | |
| SCHEMBL16316844 | 0.85 | LMNA (0.59) | ALDH1A1LMNATSHRKDM4EHPGD | |
| SCHEMBL14535420 | 0.85 | ALDH1A1 (0.59) | ALDH1A1LMNATSHRKDM4EHPGD | |
| SCHEMBL11139016 | 0.85 | LMNA (0.59) | ALDH1A1LMNATSHRKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4384115-A | Process for preparing tetrahydro-1,3-oxazin-2-ones | THE DOW CHEMICAL COMPANY (US) | 1983-05-17 | — | — | US | claimed |
| EP-3527600-B1 | ISOCYANATE COMPOSITION AND PRODUCTION METHOD FOR ISOCYANATE POLYMER | ASAHI CHEMICAL IND (JP) | 2025-07-09 | — | — | EP | disclosed |
| EP-4395763-A1 | METHODS AND COMPOSITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | AXSOME THERAPEUTICS (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230114799-A1 | ISOCYANATE COMPOSITION AND METHOD FOR PRODUCING ISOCYANATE POLYMER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-04-13 | — | — | US | disclosed |
| WO-2023034944-A1 | METHODS AND COMPOSITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | AXSOME THERAPEUTICS (US) | 2023-03-09 | — | — | WO | disclosed |
| US-11548975-B2 | Isocyanate composition and method for producing isocyanate polymer | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-01-10 | — | — | US | disclosed |
| EP-3536683-B1 | POLYISOCYANATE COMPOSITION AND ISOCYANATE POLYMER COMPOSITION | ASAHI CHEMICAL IND (JP) | 2021-11-24 | — | — | EP | disclosed |
| CN-108976272-B | 3, 3-disubstituted 19-norpregnane compounds, compositions, and uses thereof | 萨奇治疗股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10875883-B2 | Method for synthesizing novel chiral ligand, metal chelate, a variety of non-natural amino acids, maraviroc and key intermediate thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-12-29 | — | — | US | disclosed |
| EP-3372579-B1 | POLYISOCYANATE COMPOSITION AND ISOCYANATE POLYMER COMPOSITION | ASAHI CHEMICAL IND (JP) | 2020-10-28 | — | — | EP | disclosed |
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012029067-A1 | CRYSTALLINE FORMS OF MARAVIROC PHOSPHATE AND PROCESS FOR MARAVIROC AMORPHOUS FORM | HETERO RESEARCH FOUNDATION (IN) | 2012-03-08 | — | — | WO | disclosed |
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| US-7671072-B2 | Aminopyrazole derivatives as GSK-3 inhibitors | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-11-29 | — | — | US | disclosed |
| US-6967196-B1 | Sulfonamide compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| EP-1436255-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003024924-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| US-4654347-A | USEFUL AS ANXIOLYTIC AND ANTIEPILEPTIC AGENTS, SEDATIVE-HYPNOTIC AGENTS AND SKELETAL MUSCLE RELAXANTS | AMERICAN CYANAMID COMPANY (US) | 1987-03-31 | — | — | US | disclosed |
| US-4384115-A | Process for preparing tetrahydro-1,3-oxazin-2-ones | THE DOW CHEMICAL COMPANY (US) | 1983-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548975-B2 | Isocyanate composition and method for producing isocyanate polymer | IDH3A, IDH2, IDH3B | ALDH1A1 643/4885LMNA 2021/4885TSHR 4885/4885 |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | ALDH1A1 1036/4885LMNA 1974/4885TSHR 2037/4885 |
| US-10875883-B2 | Method for synthesizing novel chiral ligand, metal chelate, a variety of non-natural amino acids, maraviroc and key intermediate thereof | PRMT3, GRIN3A, RAMP3 | ALDH1A1 3474/4885LMNA 2625/4885TSHR 4110/4885 |
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ALKBH3, CPS1, APEH | ALDH1A1 574/4885LMNA 2324/4885TSHR 2998/4885 |
| US-20230114799-A1 | ISOCYANATE COMPOSITION AND METHOD FOR PRODUCING ISOCYANATE POLYMER | IDH3A, IDH2, IDH3B | ALDH1A1 666/4885LMNA 1933/4885TSHR 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.